Literature DB >> 28589868

[Two-year follow-up of infants born at 24 weeks gestation; first outcomes following implementation of the new 'Guideline for perinatal policy in cases of extreme prematurity'].

C S H Aarnoudse-Moens1, M Rijken, R M Swarte, P Andriessen, H J Ter Horst, S M Mulder-de Tollenaer, C Koopman-Esseboom, A R C Laarman, K Steiner, A H B M van der Hoeven, R F Kornelisse, J J Duvekot, N Weisglas-Kuperus.   

Abstract

OBJECTIVE: Since 2010 the guideline 'Guideline for perinatal policy in cases of extreme prematurity' has advised an active policy in infants born at 24 weeks gestation. We investigated how infants born at 24 and 25 weeks gestation in the first year following the implementation of the guideline had developed by the age of 2 years.
DESIGN: Retrospective national cohort study.
METHOD: The study population consisted of all surviving infants born in the Netherlands at 24 or 25 weeks gestation in the period from 1 October 2010 to 1 October 2011. At a corrected age of 2 years the children underwent a general physical and neurological examination, and their cognitive scores were determined on the 'Bayley scales of infant and toddler development' (Bayley III). Examinations took place in the 10 neonatal intensive care units (NICU's) in the Netherlands.
RESULTS: Of 185 extremely premature infants, 166 were admitted to a NICU. A total of 95 survived to a corrected age of 2 years; 78 (82%) children were examined. Their average cognitive score on the Bayley III scale was 88 (SD: 16). Among the children born at 24 weeks gestation, 20% had mild disabilities and 20% had moderate to severe disabilities. Among the children born at 25 weeks gestation, 17% had mild disabilities and 12% had moderate to severe disabilities.
CONCLUSION: Of the children born at 24 weeks gestation in the first year after the introduction of active policy in the Netherlands and surviving to 2 years of age (46%), more than half had developed without disabilities. This was comparable to children born at 25 weeks gestation. Of all children born at 24 weeks gestation, 25% survived to 2 years of age without disabilities.

Entities:  

Mesh:

Year:  2017        PMID: 28589868

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  4 in total

1.  Pulmonary hypertension in extremely preterm infants: a call to standardize echocardiographic screening and follow-up policy.

Authors:  Sanne Arjaans; Elvira A H Zwart; Marc Roofthooft; Elisabeth M W Kooi; Arend F Bos; Rolf M F Berger
Journal:  Eur J Pediatr       Date:  2021-02-02       Impact factor: 3.183

2.  Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017.

Authors:  Kasia Trzcionkowska; Wouter B H J Vehmeijer; Frank T Kerkhoff; Noel J C Bauer; Carlien A M Bennebroek; Peter H Dijk; Koen P Dijkman; Frank A M van den Dungen; Cathrien A Eggink; Robert P G Feenstra; Floris Groenendaal; Arno F van Heijst; Mark A H B M van der Hoeven; Rene F Kornelisse; Elke Kraal-Biezen; Enrico Lopriore; Wes Onland; Victor W Renardel de Lavalette; Laurentius J van Rijn; Frank A B A Schuerman; Huibert J Simonsz; Elsbeth S M Voskuil-Kerkhof; Ruben S G M Witlox; Jacqueline U M Termote; Nicoline E Schalij-Delfos
Journal:  Acta Ophthalmol       Date:  2020-07-23       Impact factor: 3.761

3.  Digital decision aid for prenatal counseling in imminent extreme premature labor: development and pilot testing.

Authors:  Josephus F M van den Heuvel; Marije Hogeveen; Margo Lutke Holzik; Arno F J van Heijst; Mireille N Bekker; Rosa Geurtzen
Journal:  BMC Med Inform Decis Mak       Date:  2022-01-06       Impact factor: 2.796

4.  Two-year neurodevelopmental outcome in children born extremely preterm: the EPI-DAF study.

Authors:  Pauline E van Beek; Monique Rijken; Lisa Broeders; Hendrik J Ter Horst; Corine Koopman-Esseboom; Ellen de Kort; Céleste Laarman; Susanne M Mulder-de Tollenaer; Katerina Steiner; Renate Mc Swarte; Elke van Westering-Kroon; S Guid Oei; Aleid G Leemhuis; Peter Andriessen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2022-03-02       Impact factor: 6.643

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.